StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Adempas / Verquvo (sGC stimulator alliance with Bayer by Quarter

Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Adempas / Verquvo (sGC stimulator alliance with Bayer: $126M in Q2 2026, up 2.4% from a year earlier.

Latest, Q2 2026
126
Period ended Jun 30, 2026
Change on a year earlier
+2.4%
123 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
7
Documents cited below

Where the Q2 2026 figure comes from

“|| Alliance Revenue - Adempas/Verquvo (5) | 126 | 123 | 3 | 112 | 108 | 4 | 14 | 15 | -1”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAdempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — Worldwide sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026126+2.4%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026109+2.8%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 2025129+18.3%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q3 2025Sep 30, 2025112+9.8%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q2 2025Jun 30, 2025123+16.0%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 2025106+8.2%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2024Dec 31, 2024109+0.9%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 2024102+10.9%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q2 2024Jun 30, 2024106+55.9%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q1 2024Mar 31, 202498-1.0%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q4 2023Dec 31, 2023108+31.7%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 202392+4.5%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2023Jun 30, 202368-30.6%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q1 2023Mar 31, 202399+37.5%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q4 2022Dec 31, 202282-12.8%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 202288-12.0%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗

Breakdown

What makes up adempas / Verquvo (sGC stimulator alliance with Bayer

Cite this data

StockData. (2026). Merck Adempas / Verquvo (sGC stimulator alliance with Bayer ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-adempas-verquvo

See every metric in the Merck KPI table. Data updated Oct 26, 2026.